Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

Journal of Clinical Oncology

Volumn 22, Issue 13, 2004, Pages 2532-2539

  Dahut, William L ^a   Gulley, James L ^a   Arlen, Philip M ^a   Liu, Yinong ^a   Fedenko, Katherine M ^a   Steinberg, Seth M ^a   Wright, John J ^a   Parnes, Howard ^a   Chen, Clara C ^a   Jones, Elizabeth ^a   Parker, Catherine E ^a   Linehan, W Marston ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; DOCETAXEL; LOW MOLECULAR WEIGHT HEPARIN; PROSTATE SPECIFIC ANTIGEN; THALIDOMIDE; ANTINEOPLASTIC AGENT; TAXOID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; VEIN THROMBOSIS; ADULT; AGED; DISEASE FREE SURVIVAL; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROSTATE TUMOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TAXOIDS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 4344682179     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.05.074     Document Type: Article

References (42)

1. Jemal A, Murray T, Samuels A, et al: Cancer statistics, 2003. CA Cancer J Clin 53:5-26, 2003
2. Rini BI, Small EJ: An update on prostate cancer. Curr Opin Oncol 13:204-211, 2001
3. Figg WD, Feuer J, Bauer KS: Management of hormone-sensitive metastatic prostate cancer. Cancer Practice 5:258-263, 1997
4. Beedassy A, Cardi G: Chemotherapy in advanced prostate cancer. Semin Oncol 26:428-438, 1999
5. Oh WK: Chemotherapy for patients with advanced prostate carcinoma: A new option for therapy. Cancer 88:3015-3021, 2000
6. Bissery MC, Vrignaud P, Bayssas M, et al: Preclinical in vivo activity of docetaxel-containing combinations. Proc Am Soc Clin Oncol 14:489, 1995 (abstr 1599)
7. Kreis W, Budman DR, Calabro A: Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol 79:196-202, 1997
8. Haldar S, Basu A, Croce CM: Bcl2 is the guardian of microtubule integrity. Cancer Res 57:229-233, 1997
9. McDonnell TJ, Navone NM, Troncoso P, et al: Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol 157:569-574, 1997
10. Petrylak DP, Macarthur RB, O'Connor J, et al: Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 17:958-967, 1999
11. Petrylak DP: Docetaxel (Taxotere) in hormone-refractory prostate cancer. Semin Oncol 27:24-29, 2000 (suppl 3)
12. Picus J, Schultz M: Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: Preliminary results. Semin Oncol 26:14-18, 1999 (suppl 17)
13. Stirling D: Thalidomide: A novel template for anticancer drugs. Semin Oncol 28:602-606, 2001
14. D'Amato RJ, Loughnan MS, Flynn E, et al: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91:4082-4085, 1994
15. Bauer KS, Dixon SC, Figg WD: Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 55:1827-1834, 1998
16. Weber D, Rankin K, Gavino M, et al: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21:16-19, 2003
17. Marx GM, Pavlakis N, McCowatt S, et al: Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J Neurooncol 54:31-38, 2001
18. Figg WD, Dahut W, Duray P, et al: A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 7:1888-1893, 2001
19. Little RF, Wyvill KM, Pluda JM, et al: Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 18:2593-2602, 2000
20. Retter AS, Figg WD, Dahut WL: The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancer. Clin Prostate Cancer 2:153-159, 2003
21. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
22. Schultz M, Wei J, Picus J, et al: A phase II trial of docetaxel in patients with hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 17:342, 1993 (abstr 1320)
23. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
24. Bubley GJ, Carducci M, Dahut W, et al: Eligibility and response guidelines for Phase II clinical trials in androgen independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17:3461-3467, 1999
25. Baker SD, Zhao M, Ping H, et al: Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry. Anal Biochem 324:276-284, 2004
26. Kaplan E, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
27. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chem Rep 50:163-170, 1966
28. Jones A, Fujiyama C: Angiogenesis in urological malignancy: Prognostic indicator and therapeutic target. BJU Int 83:535-555, 1999
29. Lissbrant IF, Lissbrant E, Damber J, et al: Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. Scand J Urol Nephrol 35:437-452, 2001
30. Wakui S, Furusato M, Itoh T, et al: Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: A morphometric study. J Pathol 168:257-262, 1992
31. Siegal JA, Yu E, Brawer MK: Topography of neovascularity in human prostate carcinoma. Cancer 75:2545-2551, 1995
32. Weidner N, Carroll PR, Flax J, et al: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143:401-409, 1993
33. Figg WD, Kruger EA, Price DK, et al: Inhibition of angiogenesis: Treatment options for patients with metastatic prostate cancer. Invest New Drugs 20:183-194, 2002
34. Friedland D, Cohen J, Miller R Jr, et al: A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: Correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 26:19-23, 1999 (suppl 17)
35. Beer TM, Pierce WC, Lowe BA, et al: Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 12:1273-1279, 2001
36. Petrylak DP, Macarthur R, O'Connor J, et al: Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. Semin Oncol 5:28-33, 1999 (suppl 17)
37. Sinibaldi VJ, Carducci MA, Moore-Cooper S, et al: Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 94:1457-1465, 2002
38. Savarese DM, Halabi S, Hars V, et al: Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 19:2509-2516, 2001
39. Hussain M, Petrylak D, Fisher E, et al: Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: Scientific basis and design of Southwest Oncology Group Study 9916. Semin Oncol 26:55-60, 1999 (suppl 17)
40. Zangari M, Siegel E, Barlogie B, et al: Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: Implications for therapy. Blood 100:1168-1171, 2002
41. Weber D, Ginsberg C, Walker P, et al: Correlation of thrombotic/embolic events (T/E) with features of hypercoagulability in previously untreated patients before and after treatment with thalidomide (T) or thalidomide- dexamethasone (TD). Proc Am Soc Hematol 2002 (abstr 787)
42. Home MK 3rd, Figg WD, Arlen P, et al: Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer. Pharmacotherapy 23:315-318, 2003